
LOALQUE LIpegfilgrastim



For adult patients treated with cytotoxic chemotherapy, Lonquex helps to reduce the duration of neutropenia and the incidence of febrile neutropenia.



6mg Fixed dose







24-hour after chemotherapy

Abbreviated Product Information of Longuex®

Each pre-filled syringe contains 6 mg of lipegfilgrastim in 0.6 ml solution for injection. Indications: Longuex is indicated in adults for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) Dosage and administration: One 6 mg dose of lipegfilgrastim (a single pre-filled syringe) for each chemotherapy cycle should be subcutaneously administered, approximately 24 hours after cytotoxic chemotherapy, in the abdomen, upper arm or thigh. Elderly: No dose adjustment necessary. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Interaction with other medicinal products and other forms of interaction: Concomitant use of lipegfilgrastim with any chemotherapeutic medicinal product has not been evaluated in patients. Pregnancy and lactation: Not recommended in pregnancy or whilst breastfeeding. No data available with regards to fertility. Effects on ability to drive and use machines: No or negligible influence on theability to drive and use machines. Adverse reactions: Very common: musculoskeletal pains. Common: thrombocytopenia, hypokalaemia, headache, skin reactions, chest pain. Uncommon: leukocytosis, splenomegaly, hypersensitivity reactions, pulmonary adverse reactions, injection site reactions, blood alkaline phosphatase increased, blood lactate dehydrogenase increased. Special precautions for storage: Store in a refrigerator (2 °C - 8 °C), Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light. Lonquex may be removed from the refrigerator and stored below 25 °C for a maximum single period of up to 3 days. Once removed from the refrigerator, the medicinal product must be used within this period or disposed of.

"Please refer to the Summary of Product Characteristics for full details of Prescribing Information"

References:

- Shawn DeFrees, Zhi-Guang Wang, Ruye Xing, Arthur E. Scott, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology. Volume 16. Issue 9. September 2006. Pages 833–843.
- Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012 Jul 20;161(2):461-72.
- 3. Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer. 2013 Aug 14;13:386.
- Gladkov OA, Buchner A, Bias P, Müller U, Elsässer R. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Support Care Cancer. 2016 Jan;24(1):395-400.
- 5. Product Information



Pacific Healthcare (Thailand) Co., Ltd. 1011 Supalai Grand Tower, Rama III Road, Chongnonsee, Yannawa, Bangkok 10120 Tel. (662) 8812488 Fax (662) 6833373

